European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults

被引:202
作者
Clumeck, N. [1 ]
Pozniak, A. [2 ]
Raffi, F. [3 ]
机构
[1] St Pierre Univ Hosp, Dept Infect Dis, Brussels, Belgium
[2] Chelsea & Westminster Hosp, Dept HIV & Genitourinary Med, London, England
[3] CHU Nantes, F-44035 Nantes 01, France
关键词
European treatment guidelines; national policies; optimal access to care; standard of care;
D O I
10.1111/j.1468-1293.2007.00533.x
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
A working group of the European AIDS Clinical Society (EACS) have developed these guidelines for European clinicians to help them in the treatment of adults with HIV infection. This third version of the guidelines includes, as new topics, the assessment of patients at initial and subsequent clinic visits as well as post-exposure prophylaxis. A revision of the 2005 guidelines based on current data includes changes in the sections on primary HIV infection, when to initiate therapy, which drug combinations are preferred as initial combination regimens for antiretroviral-naive patients, how to manage virological failure and the treatment of HIV during pregnancy. In Europe, there is a wide range of clinical practices in antiretroviral therapy depending on various factors such as drug registration, national policies, local availability, reimbursement and access to treatment. These can vary greatly from one country to another, especially in Central and Eastern parts of Europe. These guidelines are intended to help clinicians achieve the best care for their patients. In some countries, particularly where the quality of and access to care are not optimal, these guidelines should help AIDS societies and physicians or patient group organizations to negotiate with their national health authorities with a view to implementing what should be the standard of care for HIV-infected patients all over Europe.
引用
收藏
页码:65 / 71
页数:7
相关论文
共 10 条
[1]  
[Anonymous], 8 C RETR OPP INF CHI
[2]  
Beral V, 2004, AIDS, V18, P51, DOI [10.1097/01.aids.0000096908.73209.5d, 10.1097/00002030-200401020-00006]
[3]   Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy:: a collaborative analysis of prospective studies [J].
Egger, M ;
May, M ;
Chêne, G ;
Phillips, AN ;
Ledergerber, B ;
Dabis, F ;
Costagliola, D ;
Monforte, AD ;
de Wolf, F ;
Reiss, P ;
Lundgren, JD ;
Justice, AC ;
Staszewski, S ;
Leport, C ;
Hogg, RS ;
Sabin, CA ;
Gill, MJ ;
Salzberger, B ;
Sterne, JAC .
LANCET, 2002, 360 (9327) :119-129
[4]   Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV [J].
Gallant, JE ;
DeJesus, E ;
Arribas, JR ;
Pozniak, AL ;
Gazzard, B ;
Campo, RE ;
Lu, B ;
McColl, D ;
Chuck, S ;
Enejosa, J ;
Toole, JJ ;
Cheng, AK .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (03) :251-260
[5]   Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes [J].
Ledergerber, B ;
Lundgren, JD ;
Walker, AS ;
Sabin, C ;
Justice, A ;
Reiss, P ;
Mussini, C ;
Wit, F ;
Monforte, AD ;
Weber, R ;
Fusco, G ;
Staszewski, S ;
Law, M ;
Hogg, R ;
Lampe, F ;
Gill, MJ ;
Castelli, F ;
Phillips, AN ;
Castelli, F ;
Fusco, GP ;
Gill, MJ ;
Hogg, R ;
Lampe, F ;
Law, M ;
Ledergerber, B ;
Lundgren, JD ;
Monforte, AD ;
Mussini, C ;
Phillips, AN ;
Reiss, P ;
Staszewski, S ;
Walker, AS ;
Rooney, P ;
Taylor, S ;
Couldwell, D ;
Austin, D ;
Block, M ;
Clemons, J ;
Finlayson, R ;
Law, M ;
Petoumenos, K ;
Quan, D ;
Smith, D ;
O'Connor, C ;
Gorton, C ;
Allen, D ;
Mulhall, B ;
Mutimer, K ;
Smith, D ;
Keeffe, N .
LANCET, 2004, 364 (9428) :51-62
[6]  
MARIN B, 2007, 3 INT AIDS SOC C HIV
[7]   Tolerability of postexposure prophylaxis with the combination of zidovudine-lamivudine and lopinavir-ritonavir for HIV infection [J].
Rabaud, C ;
Burty, C ;
Grandidier, M ;
Christian, B ;
Penalba, C ;
Béguinot, I ;
Jeanmaire, H ;
May, T .
CLINICAL INFECTIOUS DISEASES, 2005, 40 (02) :303-305
[8]   Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV [J].
Schechter, M ;
do Lago, RF ;
Mendelsohn, AB ;
Moreira, RI ;
Moulton, LH ;
Harrison, LH .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 35 (05) :519-525
[9]  
STERNE J, 2006, 13 C RETR OPP INF FE
[10]  
*US DEP HHS, PUBLIC HLTH SERV TAS